Novel non-ATP competitive small molecules targeting the CK2 α/β interface

Bioorg Med Chem. 2018 Jul 15;26(11):3016-3020. doi: 10.1016/j.bmc.2018.05.011. Epub 2018 May 9.

Abstract

Increased CK2 levels are prevalent in many cancers. Combined with the critical role CK2 plays in many cell-signaling pathways, this makes it a prime target for down regulation to fight tumour growth. Herein, we report a fragment-based approach to inhibiting the interaction between CK2α and CK2β at the α-β interface of the holoenzyme. A fragment, CAM187, with an IC50 of 44 μM and a molecular weight of only 257 gmol-1 has been identified as the most promising compound. Importantly, the lead fragment only bound at the interface and was not observed in the ATP binding site of the protein when co-crystallised with CK2α. The fragment-like molecules discovered in this study represent unique scaffolds to CK2 inhibition and leave room for further optimisation.

Keywords: CK2; Fragment based drug discovery; Protein-protein interaction.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate* / chemistry
  • Binding, Competitive
  • Drug Delivery Systems*
  • Indoles / chemistry*
  • Indoles / pharmacology
  • Inhibitory Concentration 50
  • Intracellular Signaling Peptides and Proteins / chemistry*
  • Intracellular Signaling Peptides and Proteins / drug effects
  • Intracellular Signaling Peptides and Proteins / metabolism
  • Molecular Structure
  • Molecular Weight
  • Small Molecule Libraries / chemical synthesis*
  • Small Molecule Libraries / chemistry
  • Small Molecule Libraries / pharmacology

Substances

  • CAM187
  • Indoles
  • Intracellular Signaling Peptides and Proteins
  • PLEKHO1 protein, human
  • Small Molecule Libraries
  • Adenosine Triphosphate